A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, Moynahan ME, D'Andrea G, Lim K, Reddington L, Haque S, Patil S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi S.
Jhaveri K, et al. Among authors: goldfarb s.
Clin Breast Cancer. 2014 Jun;14(3):154-60. doi: 10.1016/j.clbc.2013.12.012. Epub 2013 Dec 28.
Clin Breast Cancer. 2014.
PMID: 24512858
Clinical Trial.